Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath Publishes Summer 2026 Issue of Alumni Journal

Read More

News & Insights

YRC Worldwide, Inc.’s Term Loan Facility

August 30, 2017

Cravath represented Credit Suisse, as lead arranger, in connection with the arrangement of a $600 million term loan credit facility provided to YRC Worldwide, Inc. (“YRC”) in order to refinance YRC’s existing term loan facility. This maturity extension of the term loan facility was an important liability management transaction for YRC, as it allowed YRC to focus on addressing other upcoming maturities and avoid a “springing” maturity of its asset‑based loan facility. The transaction closed on July 26, 2017.

The Cravath team was led by partner Paul H. Zumbro and included senior attorney Sarah F. Rosen and associate Steven Y. Li on banking matters and associate Aaron J. Feuer on executive compensation and benefits matters. Valerie E. Wood also worked on banking matters.

Related Practices & Industries

  • Corporate
  • Banking and Credit
  • Tax
  • Executive Compensation and Benefits
  • Transportation

People

Photo
Name
Paul H. Zumbro
Title
Corporate
Title
Partner
Email
pzumbro@cravath.com
Phone
+1-212-474-1036
vCard
Download vCard

    Education

    • J.D., 1997, Columbia Law School
      Harlan Fiske Stone Scholar
    • B.A., 1992, Yale College
      Distinction in Major, cum laude

    Admitted In

    • New York
    Name
    Sarah F. Rosen
    Title
    Corporate
    Title
    Partner
    Email
    srosen@cravath.com
    Phone
    +1-212-474-1750
    vCard
    Download vCard

      Education

      • J.D., 2005, Columbia Law School
        Harlan Fiske Stone Scholar
      • B.A., 2002, New York University
        magna cum laude

      Admitted In

      • New York

      Related News & Insights

      Deals & Cases

      July 06, 2026

      UVEX’s Upsize and Repricing of its Term Loan Facility

      Cravath represented the agent, mandated lead arrangers, and lenders in connection with the repricing of UVEX GROUP GmbH’s €400 million term loan facility and €50 million term loan add-on. UVEX GROUP GmbH is a portfolio company of Warburg Pincus. The transaction closed on June 19, 2026. 

      Deals & Cases

      April 06, 2026

      Versigent’s $1.35 Billion Credit Facilities and $1.6 Billion High‑Yield Senior Notes Offering in Connection with Aptiv PLC’s Spin‑Off of Versigent

      Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $1.35 billion of credit facilities made available to subsidiaries of Versigent Limited, a global leader in the design, development and manufacture of low voltage and high voltage electrical architectures and the holding company for Aptiv PLC’s Electrical Distribution Systems segment, which Aptiv PLC spun off into a separate, independent, publicly traded company. The proceeds were used to partially finance the spin‑off. The credit facilities consisted of a $500 million term loan facility and an $850 million revolving credit facility. The transaction closed on November 26, 2025.

      Deals & Cases

      February 20, 2026

      First Solar’s $1.5 Billion Revolving Credit Facility

      Cravath represented First Solar, Inc. in connection with its $1.5 billion revolving credit facility. First Solar is America’s leading photovoltaic solar technology and manufacturing company, and the only US‑headquartered company among the world’s largest solar manufacturers. The transaction closed on February 13, 2026.

      Deals & Cases

      January 08, 2026

      Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus

      Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.

      Cravath Bicentennial

      Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

      Explore

      Cravath, Swaine & Moore LLP Logo
      • CONTACT US
      • OUR STORY
      • ALUMNI PORTAL
      • DISCLAIMERS & NOTICES

      Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.